After leaving Harbin Pharmaceutical for 28 years, he finally pinned his pursuit of the pharmaceutical industry on this dark horse private enterprise.
On the afternoon of April 25th, it was a weekend, and the holiday Dongsheng Building in Xi 'an was very quiet. Liu, the president of Dongsheng Group, is still working in his office.
The doorman downstairs said that Mr. Liu often works overtime and sometimes works until two or three in the evening. "The work intensity is much greater than before, but the work is happy." Liu held the reporter's hand and smiled.
The hollow corridor is diagonally opposite the office of Guo Jiaxue, chairman of Dongsheng Group, looking at each other from a distance, feeling like enjoying each other. Liu is a legend. Engaged in pharmaceutical production and operation from 1976. He has been immersed in the pharmaceutical industry for nearly 30 years and has served as deputy director and director of Harbin Pharmaceutical Factory.
1August, 997, officially transferred to the chairman and general manager of Harbin Pharmaceutical Group. At that time, Harbin Pharmaceutical had 23 loss-making enterprises with a potential loss of about 530 million yuan. Subsequently, he launched a large-scale rectification of Harbin Pharmaceutical Co., Ltd. In less than three years, the main economic indicators such as output value, income and profit doubled, which strengthened the overall strength of the group. In 2000, the sales reached 6.65 billion yuan, ranking first in the sales revenue of China pharmaceutical industry.
By the end of June, 5438 +65438 10+May, 2004, Harbin Pharmaceutical Group led by Liu had accumulated profits and taxes of 5.6 billion yuan, so Liu himself was praised as the "godfather of Harbin Pharmaceutical" by the industry and became one of the well-known godfather managers in the domestic pharmaceutical industry.
In 2000, Harbin Pharmaceutical Co., Ltd. walked out of the predicament of loss, but there were new problems to be solved urgently. At that time, the main source of Harbin Pharmaceutical's profits-health care products marketed by advertising, with the emergence of a new generation of health care products and the increasingly standardized health care products market, the risks are increasing day by day.
Liu gradually realized that when product management develops to a certain extent, enterprises must combine product management with capital management, and then greatly improve it.
At the same time, Harbin Pharmaceutical's generous advertising cluster bombing strategy, although making the industry shine, can not be transformed into the core competitiveness of enterprises after all.
In order to further break through and "strengthen" Harbin Pharmaceutical Co., Ltd., it is urgent to take revolutionary measures in product structure adjustment, collectivization of group companies and shareholding system, and change it into a multi-share joint-stock enterprise group to "form a scientific governance structure". However, in large state-owned enterprises, it is difficult to change. Liu even needs the government's approval to replace a deputy, and he is facing difficulties.
Liu began to consciously look for a "strategic partner". In his view, Harbin Pharmaceutical Group has three criteria for choosing strategic restructuring partners: First, the brand of Harbin Pharmaceutical remains unchanged; Second, the place of registration remains unchanged; Third, personnel and cadres remain unchanged.
In fact, the most fatal problem of Harbin medicine is that it has no intellectual property rights. Therefore, it is best to introduce world-class strategic investors and bring their management, technology and mechanism to Harbin Pharmaceutical Co., Ltd. to make Harbin Pharmaceutical Co., Ltd. bigger and stronger.
"Partners must conform to Harbin Pharmaceutical's main business and must also be powerful pharmaceutical companies." Liu has said on many occasions.
With strong financial strength, the emergence of Huayuan Group, which is transforming from traditional industries to biopharmaceutical and natural medicine industries, can be described as "just in time", and the two hit it off.
At the end of 20001year, Huayuan's plan for restructuring Harbin Pharmaceutical Co., Ltd. was made public: in 20001year, Huayuan Group exchanged assets worth 500 million yuan and cash worth 500 million yuan for 47% of Harbin Pharmaceutical Co., Ltd., becoming a relatively large shareholder of Harbin Pharmaceutical Co., Ltd., with Harbin SASAC holding 44%, and Harbin Pharmaceutical management and employees holding 9%.
What Liu didn't expect was that as soon as the plan was announced, the opposing party seized the opportunity to launch a public opinion attack. Rumors such as "Harbin Pharmaceutical's cheap sale, black hole of funds", "individual leaders were suspected of personal corruption in this restructuring negotiation" and "Liu's 59-year-old phenomenon" intensified, and the restructuring of Harbin Pharmaceutical was abandoned after signing the agreement.
After Huayuan, Harbin Pharmaceutical was dazzled by the reorganization of contact enterprises. Liu, the godfather, soon discovered that in the next third round of restructuring, he lost the decision-making power of enterprise restructuring.
In the end, Fang Zhongxin Group, a financial investment company, won the competition with Dongsheng Group, Huayuan Group and other enterprises, and obtained the controlling stake of Harbin Pharmaceutical Group. Harbin pharmaceutical co., ltd. acquired its equity for three years, and the truth came out.
Liu's next resignation seems reasonable. "My early retirement is indeed related to the entry of CITIC Group." Liu frankly said that CITIC Group, as a financial investor, has no medical background and does not meet the real purpose of Harbin Pharmaceutical Co., Ltd. "All this was decided by Harbin SASAC, and we have no right to speak; I can only resign, otherwise I will take risks. "
It seems that the government and enterprises are not completely consistent in the selection criteria for the objectives and objects of restructuring. When there is a contradiction between the two, only the latter can compromise. Only one week after resigning from Harbin Pharmaceutical, Liu received invitations from many well-known domestic pharmaceutical companies. Go to Huayuan, or Health Yuan, or Chinese Medicine? For a time, his whereabouts became the focus of attention in the industry.
Twenty days later, Liu suddenly appeared as the director of Xinyunyao at the opening ceremony of Xinyunyao Group held in Kunming International Convention and Exhibition Center, Yunnan, and the chairman of Dongsheng Group became the chairman of Xinyunyao.
Some people speculate: Will Liu Genghong Zhou Cun finally accept the olive branch extended by Dongsheng? In fact, as early as a month ago, Liu had already served as the director and CEO of Dongsheng Group.
What made Liu finally choose Hesheng?
Liu Zeng said that he and he met at a meeting of the Tenth National People's Congress two years ago. Their strategic thinking on enterprise management and their understanding of the pharmaceutical industry coincided, resulting in the idea of "Harbin Pharmaceutical Co., Ltd. and Dongsheng Co., Ltd. for capital cooperation", but in the end they failed to do so. It is also fate that they have come to this day.
Anyone familiar with Liu knows that he is an entrepreneur with dreams. "Making Harbin Pharmaceutical bigger and stronger and bringing Harbin Pharmaceutical into the top 50 pharmaceutical companies in the world" has been his long-cherished wish for many years, but now it has left a broken mess in his mind.
With the cognition that "as a leader of an enterprise, you must be a dreamer", Guo Jiaxue is undoubtedly a dreamer. "The ideal of * * * has brought us together." Guo Jiaxue said.
"Although Liu's age is 1.5 times, he is a very passionate person. I think his passion is no less than that of a 30-year-old boy. " Guo Jiaxue, a 39-year-old passionate entrepreneur, commented on the 60-year-old passionate old man.
When Liu entered Dongsheng, the Dongsheng chariot led by him was preparing to stop the dragon slayer in Bingzhou, cultivate his mind and cultivate his internal strength. Liu, who has a lot of experience in the integration of pharmaceutical industry and enterprise management, is a match made in heaven and is more suitable to be the "leader" of Dongsheng's "second venture".
"Teacher Liu is good at refined management, and I am more suitable for extensive strategic management, which is highly complementary." He said that the division of labor between him and Liu is the integration of strategic planning and internal management.
Liu doesn't want to talk more about his six months working in Dongsheng. "I'll invite you to discuss it in detail when I have the result." Liu held her breath and vowed to do something famous. He may also realize that the glory of Harbin Pharmaceutical has gradually drifted away, and the future needs results to prove it. He is as stubborn as ever about his work.
However, after only working for half a year, Guo Jiaxue spoke highly of him: the cooperation between us is very tacit, and he has a good running-in with the management team and is deeply loved by employees. From the constrained state-owned enterprise system, a macho man plunged into the ocean of free private enterprises, and Liu's short-lived pleasure was fleeting. What awaits him is challenges and complicated work, which is not easy at all.
In two months, he went to more than 20 factories in Dongsheng. As soon as the investigation is over, we can't wait to shift our focus to the integration planning of Dongsheng's internal resources.
The overall goal of Dongsheng's "second venture" is grand: by 2009, in five years, the group's turnover will reach 4 billion US dollars, and enterprises will enter the top 30 pharmaceutical companies in the world. At the same time, optimize the product structure, market the R&D system, brand the marketing, maximize the profitability, diversify the financing channels, internationalize the development of enterprises, and comprehensively enhance the competitiveness of enterprises.
The goal is far away, and the realization of the strategy needs tactical support. Liu quickly sorted out four things that Dongsheng urgently needs to do at present.
First, strengthen the logistics system and extend the industrial chain capacity; The second is to focus on building five platforms: over-the-counter drugs with Dongsheng Technology as the core, prescription drugs with Qianjiang Pharmaceutical as the core, classic Chinese medicine with Shanxi Guangyuyuan Chinese medicine as the core, modern plant medicine with Yunyao Group as the core, and modern medical logistics with Hebei Dongsheng Huaying and Xinjiang New Special Medicine as the core; The third is to optimize the product structure; The fourth is to pave the way for the internationalization of enterprises.
For every professional manager, the most sensitive word is performance. Not to mention, the big turnover target of $4 billion is Yunnan Baiyao acquired last year. According to the commitments of both parties, by 2007, Yunyao Group will achieve the goal of annual sales of 654.38+0.2 billion yuan and net profit of 3.4 billion yuan. The headquarters of the new company established by both parties cannot be moved, the assets cannot be mortgaged and the drug certificate cannot be transferred. At the same time, 3%~5% of the income will be used for research and development every year.
If 80% of the expected sales target cannot be achieved within three years, Dongsheng must quit, and at the same time, tax and other related income should be deducted.
These hard indicators, which are almost impossible to complete in the eyes of the industry, test the wisdom of Liu, the airborne CEO.
For Dongsheng, who has established an open corporate culture, the incident of "airborne" professional managers has been continuous since 1997. 60% of Dongsheng's senior management team has working experience in multinational companies, 30% are foreigners or people from Hong Kong and Taiwan, and many of them are airborne.
However, the CEO's airborne may be the first time. Liu Can Zhou Cun successfully spread his enthusiasm for the pharmaceutical industry in Dongsheng? We will wait and see.